PCSK9 and lipid metabolism and atherosclerosis: animal models

Abstract

PCSK9 is a secreted protein that binds to the LDL receptor on the cell surface, is endocytosed along with the receptor, and interferes with its ability to recycle to the cell surface. Instead the receptor is directed to the lysosome where it is degraded, leading to decreased levels of the receptor on the cell surface and decreased internalization of LDL. In this review, we will discuss how mice deficient in the Pcsk9 gene or hepatic overexpression due to transgenesis or viral vector mediated expression contributed to our understanding of the in vivo role of PCSK9. In addition, we will discuss how the discovery of PCSK9 and its gain of function mutants has greatly facilitated the manipulation of animals modelling atherosclerosis to induce hypercholesterolemia and atherosclerosis.

Keywords

PCSK9 / LDL receptor / hyperlipidemia / atherosclerosis / mice / pig / animal models of atherosclerosis / knockout / transgenic / viral mediated

References

[1] Goldstein JL.A century of cholesterol and coronaries: from plaques to genes to statins.Cell2015;161:161-72 PMCID:PMC4525717

[2] Zhang L,Fong LG,Tontonoz P.Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.Arterioscler Thromb Vasc Biol2012;32:2541-6 PMCID:PMC4280256

[3] Abifadel M,Rabès JP.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.Nat Genet2003;34:154-6

[4] Timms KM,Samuels ME.A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.Hum Genet2004;114:349-53

[5] Leren TP.Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.Clin Genet2004;65:419-22

[6] Schlüter K-D,Schreckenberg R.Coming back to physiology: Extra hepatic functions of proprotein convertase Subtilisin/Kexin type 9.Front Physiol2020;11:598649 PMCID:PMC7750466

[7] Stoekenbroek RM,Cariou B.Inhibiting PCSK9 - biology beyond LDL control.Nat Rev Endocrinol2019;15:52-62

[8] Schulz R,Laufs U.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Basic Res Cardiol2015;110:4 PMCID:PMC4298671

[9] Lambert G,Choque B,Hovingh GK.The PCSK9 decade.J Lipid Res2012;53:2515-24 PMCID:PMC3494258

[10] Gustafsen C,Nyegaard M.The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion.Cell Metab2014;19:310-8

[11] Tavori H,Minnier J.PCSK9 association with lipoprotein(a).Circ Res2016;119:29-35 PMCID:PMC4920709

[12] Grefhorst A,Lagace TA.Plasma PCSK9 preferentially reduces liver LDL receptors in mice.J Lipid Res2008;49:1303-11 PMCID:PMC2386900

[13] Ni YG,Orsatti L.A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.J Biol Chem2010;285:12882-91 PMCID:PMC2857140

[14] Borchardt RA.Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion.J Biol Chem1987;262:16394-402

[15] Blasiole DA,Attie AD.The physiological and molecular regulation of lipoprotein assembly and secretion.Mol Biosyst2007;3:608-19

[16] Shapiro MD.PCSK9 and atherosclerosis - lipids and beyond.J Atheroscler Thromb2017;24:462-72 PMCID:PMC5429160

[17] Twisk J,Tebon A,Barrett PH.The role of the LDL receptor in apolipoprotein B secretion.J Clin Invest2000;105:521-32 PMCID:PMC289165

[18] Horton JD,Hobbs HH.Molecular biology of PCSK9: its role in LDL metabolism.Trends Biochem Sci2007;32:71-7 PMCID:PMC2711871

[19] Davignon J,Seidah NG.The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.Curr Atheroscler Rep2010;12:308-15

[20] Rosenson RS,Fazio S.The evolving future of PCSK9 inhibitors.J Am Coll Cardiol2018;72:314-29

[21] Sabatine MS.PCSK9 inhibitors: clinical evidence and implementation.Nat Rev Cardiol2019;16:155-65

[22] Raal FJ,Sabatine MS.PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.J Lipid Res2016;57:1086-96 PMCID:PMC4878192

[23] Ray KK,Kallend D.Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.N Engl J Med2020;382:1507-19

[24] Jeong HJ,Kim KS,Yoon D.Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.J Lipid Res2008;49:399-409

[25] Sun L,Li Q.Activation of adiponectin receptor regulates proprotein convertase Subtilisin/Kexin Type 9 expression and inhibits lesions in ApoE-deficient mice.Arterioscler Thromb Vasc Biol2017;37:1290-300

[26] Rashid S,Garuti R.Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.Proc Natl Acad Sci U S A2005;102:5374-9 PMCID:PMC556275

[27] Zaid A,Essalmani R.Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.Hepatology2008;48:646-54

[28] Lagace TA,Garuti R.Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.J Clin Invest2006;116:2995-3005 PMCID:PMC1626117

[29] Herbert B,Waddington SN.Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.Arterioscler Thromb Vasc Biol2010;30:1333-9

[30] Maxwell KN.Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.Proc Natl Acad Sci U S A2004;101:7100-5 PMCID:PMC406472

[31] Park SW,Horton JD.Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.J Biol Chem2004;279:50630-8

[32] Lalanne F,Amar MJ.Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.J Lipid Res2005;46:1312-9

[33] Denis M,Zaid A.Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.Circulation2012;125:894-901

[34] Tavori H,Predazzi IM.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.Cardiovasc Res2016;110:268-78 PMCID:PMC4836631

[35] Seidah NG,Wickham L.The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.Proc Natl Acad Sci U S A2003;100:928-33 PMCID:PMC298703

[36] Rashid S,Brown PE.Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.Circulation2014;130:431-41 PMCID:PMC4115295

[37] Levy E.PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.Atherosclerosis2013;227:297-306

[38] Wang Y,Hobbs HH.Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR.J Lipid Res2012;53:1932-43 PMCID:PMC3413232

[39] Thedrez A,Passard M.Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.Arterioscler Thromb Vasc Biol2016;36:1647-50

[40] Choi S,Srivastava U.Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9.Lipids Health Dis2013;12:112 PMCID:PMC3751695

[41] Benjannet S,Essalmani R.NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.J Biol Chem2004;279:48865-75

[42] Bjørklund MM,Hagensen MK.Induction of atherosclerosis in mice and hamsters without germline genetic engineering.Circ Res2014;114:1684-9

[43] Roche-Molina M,Cruz FM.Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.Arterioscler Thromb Vasc Biol2015;35:50-9

[44] Vozenilek AE,Schilke RM.AAV8-mediated overexpression of mPCSK9 in liver differs between male and female mice.Atherosclerosis2018;278:66-72 PMCID:PMC6263847

[45] Jarrett KE,De Giorgi M.Somatic editing of ldlr with adeno-associated viral-CRISPR is an efficient tool for atherosclerosis research.Arterioscler Thromb Vasc Biol2018;38:1997-2006 PMCID:PMC6202188

[46] Peled M,Weinstock A.A wild-type mouse-based model for the regression of inflammation in atherosclerosis.PLoS One2017;12:e0173975 PMCID:PMC5349694

[47] Fisher EA.Regression of atherosclerosis: the journey from the liver to the plaque and back.Arterioscler Thromb Vasc Biol2016;36:226-35 PMCID:PMC4732981

[48] Swirski FK,Aikawa E.Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata.J Clin Invest2007;117:195-205 PMCID:PMC1716211

[49] Basu D,Huggins LA.Novel reversible model of atherosclerosis and regression using oligonucleotide regulation of the LDL receptor.Circ Res2018;122:560-7 PMCID:PMC5815899

[50] Ding Z,Wang X.Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.Antioxid Redox Signal2015;22:760-71 PMCID:PMC4361218

[51] Ferri N,Pirillo A.Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.Atherosclerosis2012;220:381-6

[52] Giunzioni I,Covarrubias R.Local effects of human PCSK9 on the atherosclerotic lesion.J Pathol2016;238:52-62 PMCID:PMC5346023

[53] Ding Z,Goel A,Mehta JL.PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1.Cardiovasc Res2020;116:908-15

[54] Ding Z,Wang X.PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages.Cardiovasc Res2018;114:1145-53

[55] Getz GS.Animal models of atherosclerosis.Arterioscler Thromb Vasc Biol2012;32:1104-15 PMCID:PMC3331926

[56] Shim J,Sørensen CB.Large animal models of atherosclerosis--new tools for persistent problems in cardiovascular medicine.J Pathol2016;238:257-66

[57] Lee YT,Lin HY.Animal models of atherosclerosis.Biomed Rep2017;6:259-66 PMCID:PMC5403338

[58] Al-Mashhadi RH,Kragh PM.Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.Sci Transl Med2013;5:166ra1

[59] Yuan F,Park KH.Ossabaw pigs with a PCSK9 gain-of-function mutation develop accelerated coronary atherosclerotic lesions: A novel model for preclinical studies.J Am Heart Assoc2018;7:e006207 PMCID:PMC5907533

[60] Hedayat AF,Kwon TG.Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model.Transl Res2018;192:30-45 PMCID:PMC5811343